Stocklytics Platform
Asset logo for symbol BVS
Bioventus
BVS57
$10.54arrow_drop_down2.72%-$0.29
Asset logo for symbol BVS
BVS57

$10.54

arrow_drop_down2.72%
Key Stats
Open$10.85
Prev. Close$10.84
EPS-0.61
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range10.04
10.94
52 Week Range2.85
14.37
Ratios
EPS-0.61
Fundamentals
Payout Ratio-
Industry average yield3.25%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

BVS-
US Healthcare Sector-
US Market-
warning

BVS / Market

BVS lose to the US Market which returned -0.68% over the last twenty four hours.
warning

BVS / Healthcare Sector

BVS lose to the US Healthcare sector which returned 1.01% over the last twenty four hours.

Bioventus (BVS) Statistics

Bioventus Inc. (BVS) is a leading global provider of orthobiologic solutions. With a focus on healing, the company develops and markets innovative products for the treatment of musculoskeletal conditions. Bioventus is committed to improving patient outcomes through advanced therapies that promote the body's natural healing process. The company's products are utilized by healthcare professionals worldwide to help patients recover faster and return to a more active lifestyle.
In terms of stock statistics, Bioventus Inc. (BVS) has had a strong performance in the market. The stock has shown positive growth over the years, outperforming its sector average. This is reflected in the company's valuation metrics, which indicate a favorable market perception of Bioventus Inc. The stock's fundamentals are also solid, with a healthy profit margin and gross profit. Additionally, Bioventus Inc.'s total debt remains manageable, indicating financial stability.
add Bioventus to watchlist

Keep an eye on Bioventus

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Bioventus (BVS) stock's performance compared to its sector and the market over the past year?

Over the past year, Bioventus (BVS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 19.05%, Bioventus has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 43.77%, it has fallen short of the market average. This comparison highlights Bioventus's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Bioventus (BVS) stock?

The PE ratio for Bioventus (BVS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Bioventus (BVS) stock?

The Earnings Per Share (EPS) for Bioventus (BVS), calculated on a diluted basis, is -$0.61. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Bioventus (BVS) stock?

The operating margin for Bioventus (BVS) is 4.78%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Bioventus (BVS) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Bioventus (BVS) is $68.32M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Bioventus (BVS) have?

Bioventus (BVS) has a total debt of $405.07M. The net debt, which accounts for cash and cash equivalents against the total debt, is $340.51M.

Take Your Investments to a Whole New Level